Merkel Cell Carcinoma Disease Treatment Market - Forecasts from 2019 to 2024

December 2019 | 122 pages | ID: M676BADEFA19EN
Knowledge Sourcing Intelligence LLP

Abstracts

The merkel cell carcinoma disease treatment market was valued at US$2.914 billion in 2018 and is anticipated to grow at a CAGR of 3.13% to reach a market size of US$3.506 billion by 2024. The presence of the merkel cells can be found in the touch-sensitive area of the epidermis, which is also known as the outermost layer of the skin. Merkel cell carcinoma is considered to be an aggressive form of skin cancer that metastasizes very fast to other areas of the body. There are several drugs are in the pipeline for the development of effective disease treatment. However, the exact cause of the disease is unknown, but excessive sunlight exposure and a weakened immune system may aggravate the risk of cancer. Rising disease incidence, rising healthcare expenditure, and growing research and development investments are driving the growth of the merkel cell carcinoma disease treatment market in the forecast period. Europe and North America are expected to hold a significant market share due to the growing incidences of this disease in the United States, France, Germany, and Sweden among other regions. Additionally, China and Australia from the APAC region also have growing incidences of Merkel cell carcinoma where the market may thrive owing to the need for disease treatment in these regions.

The Merkel Cell Carcinoma Disease Treatment Market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by treatment, by disease stage, and by geography.

The merkel cell carcinoma disease treatment market has been segmented based on treatment, disease stage, and geography. On the basis of treatment, the market has been segmented into immunotherapy, surgical excision, radiation therapy, and others. On the basis of disease stage, the market is categorized into local (skin only), nodal (includes lymph nodes), and metastatic (spreads elsewhere in the body).

Regional analysis has been provided with detailed analysis and forecast for the period 2018 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa (MEA), and the Asia Pacific regions. The report also analyzes 16 major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.

Major players in the merkel cell carcinoma disease treatment market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the merkel cell carcinoma disease treatment market.

Segmentation:

• By Treatment
• Immunotherapy
• Surgical Excision
• Radiation Therapy
• Others
• By Disease Stage
• Local (Skin only)
• Nodal (includes lymph nodes)
• Metastatic (spreads elsewhere in the body)
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• UAE
• Others
• Asia Pacific
• China
• Japan
• South Korea
• India
• Others

'The report will be delivered in 3 working days.'

Contents

1. INTRODUCTION

1.1. Market Definition
1.2. Market Segmentation

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Prevalence
  4.3.1. By age group
  4.3.2. By gender
  4.3.3. By region
4.4. Product Pipeline
4.5. Innovations

5. MERKEL CELL CARCINOMA DISEASE TREATMENT MARKET ANALYSIS, BY TREATMENT

5.1. Introduction
5.2. Immunotherapy
5.3. Surgical Excision
5.4. Radiation Therapy
5.5. Others

6. MERKEL CELL CARCINOMA DISEASE TREATMENT MARKET ANALYSIS, BY DISEASE STAGE

6.1. Introduction
6.2. Local (Skin only)
6.3. Nodal (includes lymph nodes)
6.4. Metastatic (spreads elsewhere in the body)

7. MERKEL CELL CARCINOMA DISEASE TREATMENT MARKET ANALYSIS, BY GEOGRAPHY

7.1. Introduction
7.2. North America
  7.2.1. North America merkel cell carcinoma disease treatment Market, By Treatment, 2018 to 2024
  7.2.2. North America merkel cell carcinoma disease treatment Market, By Disease Stage, 2018 to 2024
  7.2.3. By Country
    7.2.3.1. USA
      7.2.3.1.1. By Treatment
      7.2.3.1.2. By Disease Stage
    7.2.3.2. Canada
      7.2.3.2.1. By Treatment
      7.2.3.2.2. By Disease Stage
    7.2.3.3. Mexico
      7.2.3.3.1. By Treatment
      7.2.3.3.2. By Disease Stage
7.3. South America
  7.3.1. South America merkel cell carcinoma disease treatment Market, By Treatment, 2018 to 2024
  7.3.2. South America merkel cell carcinoma disease treatment Market, By Disease Stage, 2018 to 2024
  7.3.3. By Country
    7.3.3.1. Brazil
      7.3.3.1.1. By Treatment
      7.3.3.1.2. By Disease Stage
    7.3.3.2. Argentina
      7.3.3.2.1. By Treatment
      7.3.3.2.2. By Disease Stage
    7.3.3.3. Others
7.4. Europe
  7.4.1. Europe merkel cell carcinoma disease treatment Market, By Treatment, 2018 to 2024
  7.4.2. Europe merkel cell carcinoma disease treatment Market, By Disease Stage, 2018 to 2024
  7.4.3. By Country
    7.4.3.1. Germany
      7.4.3.1.1. By Treatment
      7.4.3.1.2. By Disease Stage
    7.4.3.2. France
      7.4.3.2.1. By Treatment
      7.4.3.2.2. By Disease Stage
    7.4.3.3. United Kingdom
      7.4.3.3.1. By Treatment
      7.4.3.3.2. By Disease Stage
    7.4.3.4. Spain
      7.4.3.4.1. By Treatment
      7.4.3.4.2. By Disease Stage
    7.4.3.5. Others
7.5. Middle East and Africa
  7.5.1. Middle East and Africa merkel cell carcinoma disease treatment Market, By Treatment, 2018 to 2024
  7.5.2. Middle East and Africa merkel cell carcinoma disease treatment Market, By Disease Stage, 2018 to 2024
  7.5.3. By Country
    7.5.3.1. Saudi Arabia
      7.5.3.1.1. By Treatment
      7.5.3.1.2. By Disease Stage
    7.5.3.2. Israel
      7.5.3.2.1. By Treatment
      7.5.3.2.2. By Disease Stage
    7.5.3.3. UAE
      7.5.3.3.1. By Treatment
      7.5.3.3.2. By Disease Stage
    7.5.3.4. Others
7.6. Asia Pacific
  7.6.1. Asia Pacific merkel cell carcinoma disease treatment Market, By Treatment, 2018 to 2024
  7.6.2. Asia Pacific merkel cell carcinoma disease treatment Market, By Disease Stage, 2018 to 2024
  7.6.3. By Country
    7.6.3.1. China
      7.6.3.1.1. By Treatment
      7.6.3.1.2. By Disease Stage
    7.6.3.2. Japan
      7.6.3.2.1. By Treatment
      7.6.3.2.2. By Disease Stage
    7.6.3.3. South Korea
      7.6.3.3.1. By Treatment
      7.6.3.3.2. By Disease Stage
    7.6.3.4. India
      7.6.3.4.1. By Treatment
      7.6.3.4.2. By Disease Stage
    7.6.3.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

9.1. Merck KGaA, Darmstadt, Germany
9.2. Pfizer Inc.
9.3. APCure SAS
9.4. Checkpoint Therapeutics, Inc.
9.5. Nektar Therapeutics
9.6. Philogen S.p.A.

10. APPENDIX